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Abstract 
Background: Increased cell mobility is a signature when tumor cells undergo epithelial-to-mesenchymal transition. 
TGF-β is a key stimulating factor to promote the transcription of a variety of downstream genes to accelerate cancer 
progression and metastasis, including osteopontin (OPN) which exists in several functional forms as different splic-
ing variants. In non-small cell lung cancer cells, although increased total OPN expression was observed under various 
EMT conditions, the exact constitution and the underlining mechanism towards the generation of such OPN splicing 
isoforms was poorly understood.
Methods: We investigated the possible mechanisms of osteopontin splicing variant and its role in EMT and cancer 
metastasis using NSCLC cell line and cell and molecular biology techniques.
Results: In this study, we determined that OPNc, an exon 4 excluded shorter form of Opn gene products, appeared 
to be more potent to promote cell invasion. The expression of OPNc was selectively increased to higher abundance 
during EMT following TGF-β induction. The switching from OPNa to OPNc could be enhanced by RUNX2 (a transcrip-
tion factor that recognizes the Opn gene promoter) overexpression, but appeared to be strictly in a HDAC depend-
ent manner in A549 cells. The results suggested the increase of minor splicing variant of OPNc required both (1) 
the enhanced transcription from its coding gene driven by specific transcription factors; and (2) the simultaneous 
modulation or fluctuation of the coupled splicing process that depends to selective classed of epigenetic regulators, 
predominately HDAC family members.
Conclusion: Our study not only emphasized the importance of splicing variant for its role in EMT and cancer metas-
tasis, but also helped to understand the possible mechanisms of the epigenetic controls for defining the levels and 
kinetic of gene splicing isoforms and their generations.
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Background
Lung cancer emerges as the most common cancer 
malignancy worldwide and is top ranked in both inci-
dence and mortality [1]. Although current advances in 
chemotherapy have improved the survival of patients 
with non-small cell lung cancer (NSCLC), most patients 
die because of cancer invasion and metastasis with lim-
ited life span [2]. Growing evidence have suggested that 
the process of epithelial–mesenchymal transformation 
(EMT) is an important mechanism to trigger the inva-
sion and metastasis of lung cancer cells and responsible 
for the poor prognosis of cancer patients. The current 
exploration on these EMT makers or EMT-TFs for their 
potential application in clinical diagnosis or prognosis 
could be of special interest for improving the treatments 
of lung cancers. Unfortunately, many of such attempts 
seemed to be cumbersome, as the known candidate 
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molecules (E-cadherin, vimentin, fibronectin, etc.) or 
associated TFs (ZEB1, SNAIL and TWIST, etc.) are nei-
ther sensitive enough nor easily detected from conven-
tional clinical samples. On the other hand, the searching 
for connection of currently known cancers markers for 
its connection to EMT regulation became an alternative 
solution for validating possible clinical marker indicating 
changes in EMT phenotype. To this end, a canonical can-
cer marker protein osteopontin (OPN) deserves immedi-
ate attention.
OPN is implicated in the progression of fibrosis, can-
cer, and other metastatic disease in multiple organ 
systems [3]. From recent reports, OPN was also dem-
onstrated as a key regulator to EMT programs in can-
cers [4]. It was shown that OPN was able to drive EMT 
through specific cellular signaling pathways, and also 
restructure the microenvironment during EMT stages. 
As a secretory protein which can easily detected in the 
plasma, OPN is an attractive marker for its clinical values 
in cancer diagnosis. Extracelluar OPN proteins bound to 
integrin (αvβ3) at the cell surface, and subsequently acti-
vated the  PI3K/pAkt/NF-κB pathway to regulate NF-κB/
ZEB-dependent EMT signals [5]. OPN was also found 
to upregulate hypoxia-inducible factor-1α (HIF-1α) to 
amplify EMT downstream signals upon TWIST acti-
vation. Ectopic expression of OPN induced upregula-
tion of key EMT-related transcription factors, including 
TWIST, SNAIL, and SLUG, causing enhanced cell migra-
tion with repressed E-cadherin expression [6]. In breast 
cancer cells, serine phosphorylation of TWIST resulted 
from OPN overexpression allowed its binding to the 
Blymphoma Mo-MLV promoter at the insertion region 
1 homolog (Bmi-1), which ultimately accelerated EMT 
progression in cancer cells [7].
The primary OPN transcript produces at least three 
major OPN splicing isoforms (OPN-SI), named OPNa, 
OPNb and OPNc respectively. OPNa is regarded as the 
full length isoform; OPNb and OPNc are the mutual 
excluded splicing isoforms, where the former lacks of 
exon 5 and the latter is missing exon 4 [8]. Several other 
minor isoforms of OPN with lower tissue abundance 
have also been identified, such as isoform 4 (OPN4) and 
isoform 5 (OPN5) which documented as annotated tran-
scripts in the databases of NCBI-Unigene/Nucleotide, 
EBI-ENA and UniProt [9]. OPN proteins exist in differ-
ent forms from either full-length or processed transcript 
variants, and subsequently can be further processed into 
various proteolytic fragments with or without chemical 
modifications, such as glycosylation. However, the regu-
lation and functions of OPN-SIs remain to be obscure, 
especially about whether the emergence or changes in 
expression of certain OPN-SI is sufficient to indicate the 
occurrence or progress of EMT needs to be clarified.
The regulation of alternative splicing was early revealed 
to involve elements of specific RNA sequence and their 
associated factors. Recent studies started to show that 
epigenetic regulation not only determines the genome 
DNA sequence to be transcribed, but can also define 
how the transcript to be spliced. In eukaryotic organisms, 
instead of being a next step following gene transcription, 
splicing events occur co-transcriptionally under most cir-
cumstances. Therefore, the previous recruitment model 
interpreting the splicing mechanism was evolved into a 
kinetic model for better explaining the coupling of tran-
scription and splicing processes. In the kinetic model, 
the rate of transcription could determine which cis-
elements (SREs or splice sites, derived from the recruit-
ment model) was openly accessible for spliceosomal and 
regulatory proteins at any defined moment. As a result, 
slow transcription favors the inclusion of cassette exons, 
whereas fast transcription in rate more likely to cause 
exon skipping. At the epigenetic layers, methylation of 
cytosines in DNA molecules, nucleosome occupancy, 
histone variants with modifications were implicated for 
altering the rate of transcription. For examples, histone 
acetylation on the exon–intron junctions often promotes 
skipping of exons, while deacetylation exerted opposite 
effects. Epigenetic remodeling in chromatin configura-
tion is also thought to change the rate of transcription 
elongation rate, introducing fluctuation at certain regions 
where RBPs are recruited to affect the splicing of nascent 
transcripts. In fact, the epigenetic regulation on mRNA 
splicing indeed involve common transcription factors 
that are able to bind the gene promoters. These TFs not 
only play critical roles in priming the transcription, but 
also potentially interact with HDAC family members to 
interfere the transcription rate at the elongation stages. 
It was hypothesized that the activity of TFs is highly 
dependent to chromatin configuration in context of epi-
genetic modifications, which could also be the structure 
bases for assembling of splicing regulators.
RUNX2 is discovered as a master regulator of osteo-
genesis, but is abnormally expressed in several cancer 
types, including NSCLC [10]. Altered RUNX2 function is 
involved in unchecked pathways promoting tumor pro-
gression, EMT, and metastasis [11]. Among transcrip-
tion factors that were able to regulate OPN expression, 
RUNX2 was earlier reported to modulate the expression 
and secretion levels of OPN proteins in osteosarcoma 
cells. RUNX2 was also known as a cancer-related tran-
scription factor to promote the adhesion of endothelial 
pulmonary cells and the cancer lung metastasis [12]. 
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However, whether RUNX2 could serve as a major fac-
tor contributing to the production of different OPN-SIs 
was not yet investigated. Certain OPN-SIs are increas-
ingly recognized as possible markers in several types of 
cancers. In lung cancer patients, the major spliced OPN 
forms can be detected in both pleura and tumor tis-
sues. Besides markedly upregulated OPNa, OPNc shows 
significant correlation with invasive behavior [13] and 
was found to be negatively correlated with the levels of 
E-cadherin and β-catenin [14]. The OPNc blood levels 
increased significantly as higher grade tumor was under 
development [15]. Recent studies strongly suggested that 
OPN-SI of specific types might specifically indicate cer-
tain cancer pathological features and biological functions 
of clinical meanings. In-depth investigation on OPN-SIs 
will expand the knowledge to cancer cell biology and 
could potentially lead to the discovery of referable cancer 
biomarkers.
In this study, we explored on the emergence of OPN-
SIs from the epigenetic regulation of OPN total mRNA 
transcription, as well as the physiopathological role of 
OPNc on EMT development. We characterized the role 
of RUNX2 on the regulation of different OPN-SI expres-
sion levels. The results showed that RUNX2 was able to 
alter OPN splicing in dependent to HDAC activity with 
the involvement of splicing regulator SRSF1. We also dem-
onstrated that OPNc posed a potent function to induce 
and maintain an invasive phenotype of lung cancer cells, 
where EMT signals was being activated. These findings 
are important for understanding the progression of TGF-β 
induced EMT in lung cancers, during which both RUNX2 
and OPN, in particular OPNc as a functional splicing iso-
form, were upregulated. It was also suggested that inhibi-
tors of HDACs could be potential reagents to suppress the 
production of total OPN and OPN-SIs, thus to alleviate the 
TGF-β induced EMT malignancy in lung cancers.
Materials and methods
Tissue culture and cell treatments
The human non-small cell lung cancer cell line A549 was 
obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA). Cells were maintained at 37  °C 
in a 5%  CO2 incubator in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (FBS) (Bio-
logical Industries, Kibbutz Beit Haemek, Israel) and 1% 
penicillin–streptomycin (Keygen Biotech, Nanjing, China). 
Recombinant human TGF-β (R&D Systems, Minneapolis, 
MN) was used for treating cells at 5 ng/ml for 48 h. The 
HDAC inhibitor trichostatin A (TSA) (MCE, Monmouth) 
at 60  nM or sodium butyrate (NaB) (Sangon Biotech, 
Shanghai, China) at 1 mM were used for 24 h in assays for 
evaluating epigenetic regulation of gene expression.
Human lung cancer specimen
A total of 92 NSCLC tissue samples and 90 matched adja-
cent paracancerous tissues were collected from NSCLC 
patients who received curative resection in Peking Uni-
versity Hospital. The tissue samples were treated fol-
lowing the SOP procedures immediately after surgical 
operations and stored in the Tissue Bank of Cancer 
Institute of Capital Medical University. Clinic-patholog-
ical information, including age, sex, histological types of 
tumors, TNM stage, and lymph node metastasis were 
recorded and registered into the patients’ database. Ethi-
cal approval for the present study was obtained from the 
Peking University Cancer Hospital Ethics Committee.
Plasmid or siRNA transfection
The expression cassettes of OPN-SIs (OPNa, OPNb and 
OPNc) and RUNX2 were cloned individually into pEN-
TER vectors by Vigene Bioscience Co., Ltd. (Shandong, 
China) and amplified in bacterial host cells. The siRNAs 
targeting against RUNX2 or SRSF1, shown in Table  1, 
were obtained from GenePharma (Shanghai, China). The 
siRNAs for HDAC1, HDAC2 or HDAC3 were purchased 
from Santa Cruz Biotechnology, Inc. (CA). The cells were 
either transfected with the expression plasmids or paired 
siRNA oligos for targeted gene using Lipofectamine™ 
RNAiMAX transfection Kit (Invitrogen, Massachusetts) 
using the vendor’s recommended protocols. Western 
blotting was performed to detect the resulted expres-
sion of the corresponded genes. The construct of pGL3-
6xRUNX2-Luc reporter were used in A549 cells for 
determining the transactivation for gene transcription 
levels controlled by specific promoters.
A set of minigene reporters for the splicing of OPNb 
and OPNc was constructed by Genechem Co., Ltd. 
(Shanghai, China). The synthetic sequences that match 
the targeted exon and the flanking introns were cloned 
separately into a pGL3-basic-Luc-Reporter vector 
immediately downstream of the ATG start codon of the 
luciferase gene. The splicing minigene of pGL3-OPN-
SIb-luc is the fusion of exon 4, initial 300 bp of intron 
4, last 300 bp of intron 4, exon 5, intron 5 and exon 6 
of the Opn gene. The pGL3-OPNSIc-luc minigene con-
tains fused segments of the Opn gene in the order of 
exon 3, initial 300 bp of intron 3, last 300 bp of intron 
3, exon 4, intron 4 and exon 5. The stop codons were 
engineered at the end of the alternative spliced exons, 
i.e. exon 4 or 5 for each of the two constructs as shown 
in Additional file  1: Figure S1. When cells were trans-
fected and subjected to various treatments, luciferase 
reporter assay were carried out and cross-referenced 
with the real time PCR and western blot results.
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RNA preparation and qRT‑PCR
For quantitative analyses of various OPN transcripts 
in NSCLC and paracancerous tissue, RNA extraction 
using Trizol (Life Technologies, Carlsbad), reverse tran-
scription (RT) and qPCR were performed as previously 
described [16]. OPNc qPCR primer is listed in Table  1. 
Z-sequence on qPCR primers is 5′-ACT GAA CCT GAC 
CGT ACA -3′, which is complementary to the universal Z 
probe used for the QPCR (TCS Biological Ltd., Oxford, 
UK). Real-time QPCR conditions were 95 °C for 15 min, 
followed by 60 cycles at 95 °C for 20 s, 55 °C for 30 s and 
72 °C for 20 s. The quality of cDNA samples was verified 
using β-actin as a housekeeping gene.
In the quantitative analysis of OPNa, OPNb, OPNc and 
OPNt transcripts in A549 cells, total RNA was isolated 
using Trizol (Life Technologies, Carlsbad). HiScript II 
Q RT SuperMix for qPCR Kit (Vazyme, Nanjing, China) 
was used for reverse transcription. The obtained cDNA 
was subjected to qRT-PCR assays using  NovoStart® 
SYBR qPCR SuperMix Plus (Novoprotein, Shanghai, 
China). The primers for detecting OPNt, OPNa, OPNb, 
OPNc, SRSF1 and RUNX2 are listed in Table 1. GAPDH 
was used for normalization of gene expression.
Western blotting
Western blot analysis was performed as earlier described 
[17]. Briefly, cell lysates were prepared and proteins were 
separated by 10% SDS–polyacrylamide gel electropho-
resis (SDS-PAGE), and then transferred onto polyvi-
nylidene fluoride (PVDF) filters. The probing antibodies 
used were as against the following antigens: E-cadherin 
(ab1416, mouse monoclonal antibody, 1:1000, Abcam, 
Cambridge, UK), N-cadherin (ab19348, mouse monoclo-
nal antibody, 1:1000, Abcam), Vimentin.
SNAIL (ab53519, goat polyclonal antibody, 1:1000, 
Abcam), SLUG (sc166476, mouse monoclonal antibody, 
1:1000, Santa Cruz), Twist.
OPN (ab8448, rabbit polyclonal antibody, 1:1000, 
Abcam), RUNX2 (ab115899, mouse monoclonal anti-
body, 1:4000, Abcam), SRSF1 (32–4500, mouse monoclo-
nal antibody, 1:250, Thermo Fisher Scientific, Waltham, 
MA), HDAC1 (CY5154, rabbit monoclonal antibody, 
1:1000, Abways, Shanghai, China), HDAC2 (CY5062, 
rabbit monoclonal antibody, 1:1000, Abways), HDAC3 
(CY5595, rabbit monoclonal antibody, 1:1000, Abways), 
DDDK (M185-3L, mouse monoclonal antibody, 1:1000, 
MBL, Beijing, China) and GAPDH (TA-08, mouse mono-
clonal antibody, 1:3000, ZSGB-BIO, Beijing, China).
Luciferase reporter assay
A total of 1 × 105 cells co-transfected with splicing 
reporter minigene pGL3-OPNSIb-luc or pGL3-OPNSIc-
luc and a pRenilla control were seeded in 24-well plates. 
The overexpression plasmid or siRNAs to targeting gene 
were also used for transfection by Lipofectamine™ 2000 
reagent (Invitrogen). After continuous culture for 48  h, 
the firefly and renilla luciferase activities of the collected 
lysates were measured with a Dual-Luciferase Reporter 
System (Promega, Madison, WI, USA).
Table 1 Primers for  PCR-based assays and  siRNAs used 
for transfection
Target Oligonucleotide sequence
qPCR
 OPNt F: GCC GAG GTG ATA GTG TGG TT
R: AAC GGG GAT GGC CTT GTA TG
 OPNa F: GCC GAG GTG ATA GTG TGG TT
R: AAC GGG GAT GGC CTT GTA TG
 OPNb F: ATC TCC TAG CCC CAC AGA C
R: AAA ATC AGT GAC CAG TTC ATCAG 
 OPNc F: TGA GGA AAA GCA GAA TGC TG
R: GTC AAT GGA GTC CTG GCT GT
 β-actin F: CAT TAA GGA GAA GCT GTG CT
R: ACT GAA CCT GAC CGT ACA GCT CGT 
AGC TCT TCT CCA G
 GAPDH F: GGA GCG AGA TCC CTC CAA AAT 
R: GGC TGT TGT CAT ACT TCT CATGG 
PCR
 OPN F: AGC AGA ATC TCC TAG CCC CA
R: ACG GCT GTC CCA ATC AGA AG
 E-cadherin F: TGC CCA GAA AAT GAA AAA GG
R: GTG TAT GTG GCA ATG CGT TC
 N-cadherin F: GAC AAT GCC CCT CAA GTG TT
R: CCA TTA AGC CGA GTG ATG GT
 Vimentin F: CTG CAG GAC TCG GTG GAC TT
R: GAA GCG GTC ATT CAG CTC CT
 Snail F: TAC AGC GAG CTG CAG GAC TCT AAT 
R: AGG ACA GAG TCC CAG ATG AGC ATT 
 Slug F: TGA TGA AGA GGA AAG ACT ACAG 
R: GCT CAC ATA TTC CTT GTC ACAG 
 Twist F: GCC GAC GAC AGC CTG AGC AA
R: CGC CAC AGC CCG CAG ACT TC
 RUNX2 F: ACG GCA GCG GAC AGC AGA 
R: TGC GGA TAG CAA CAC AGT TCT 
 GAPDH F: GGC TGC TTT TAA CTC TGG TA
R: GAC TGT GGT CAT GAG TCC TT
siRNA
 scramble UUC UCC GAA CGU GUC ACG UTT 
 SRSF1 CCA ACA AGA TAG AGT ATA ATT 
TGA AGC AGG TGA TGT ATG TTT 
 RUNX2 CUC UGC ACC AAG UCC UUU UTT 
GGU UCA ACG AUC UGA GAU UTT 
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Wound‑healing assay
Cells were seeded in 6-well plates until formed a con-
fluent monolayer. A straight scratch line was made in 
the monolayer using pipette tips in each well. The clos-
ing of the gaps was observed under an inverted micro-
scope during the incubation period. Digital images were 
acquired at each time point. The distance between the 
boundary edges of cell growth was measured as the quan-
tifiable index for cell migration using ImageJ software.
Cell invasion assay
Transwell chambers adapted with a 6.5  mm diameter 
polycarbonate filter insert (pore size 8  μm) (Corning, 
Corning, NY, USA) were pre-coated with 50  μg/insert 
of Matrigel (Corning). Cells were planted at a density 
of 2 × 104 cells/chamber. After incubation for 48  h, the 
cells invaded through the Matrigel were fixed, stained. 
Quantification and statistics was performed as described 
before [18].
Statistical analysis
The computer program Prism 6 (GraphPad Software, 
Inc., La Jolla, CA, USA) was used for statistical analyses. 
The association between gene expression and clinical fac-
tors was analyzed using Mann–Whitney U test. The Stu-
dent’s t test was used to compare cell functions between 
paired groups. The analysis of variance (ANOVA) was 
used to determine the statistical significance of data 
in multiple groups. The overall survival rates were cal-
culated using the Kaplan–Meier method. Cases of 
p-value < 0.05 was defined as statistically significant.
Results
Correlated upregulation of OPN and RUNX2 during TGF‑β 
induced EMT in A549 NSCLC cells
We used TGF-β to treat NSCLC cells for inducing a 
migratory phenotype in A549 cells, as it is known that 
the development of EMT could be promoted by TGF-β 
in lung tumor cells [19]. Exposed in TGF-β (5 ng/ml) for 
48  h, the cells exhibited increased mobility comparing 
to the untreat controls (p < 0.01) (Fig. 1a). Besides, a sig-
nificant percentage in TGF-β treated cells reshaped into 
a mesenchymal-like morphology from their native cob-
blestone epithelial type as in the controls. Such morpho-
logical changes towards fibroblast-like states are often 
an indication for EMT progression, therefore, we tested 
the expression of several EMT markers for their expres-
sion following TGF-β treatments in A549 cells through 
RT-PCR and western blotting. The results showed that 
both N-cadherin and Vimentin, as EMT signature mol-
ecules, were upregulated, accompanied with markedly 
downregulated E-cadherin. Other EMT-specific tran-
scription factors, such as SNAIL, SLUG and TWIST 
were also upregulated, comparing to the untreat A549 
cells (Fig.  1b). As expected, the significantly increased 
OPN was observed during EMT progress. Meanwhile, 
the expression of RUNX2, a TF could recognize the con-
served motif at a distal region of the Opn gene promoter, 
was found to be increased at both mRNA and protein 
levels in TGF-β induced A549 cells (Fig. 1c). These results 
suggested that during TGF-β induced EMT in NSCLC 
cells, the associated upregulation of RUNX2 and OPN 
might be functionally important for the development, as 
well as the progress of EMT.
RUNX2 enhanced TGF‑β induced Opn gene expression 
and promoted OPN alternative splicing
To address whether the expression of OPN splicing vari-
ants following TGF-β induction is affected with the 
changes in RUNX2 level and functions, we detected the 
mRNA levels, as well as the abundance of major OPN-SI 
species using qRT-PCR with specific primers probing for 
splicing junctions (Fig. 2a). The overexpression of wild type 
or dominant negative RUNX2 was also used for transfec-
tion to verify the OPN-SI expression under the influence 
of RUNX2 transcription regulatory activities. The results 
showed that the mRNA levels of OPNt and OPNa, OPNb, 
OPNc were increased in the TGF-β induced A549 cells 
(Fig. 2b). Noticeably, the normalized abundance of OPNc, 
calculated using the ratio of OPNc to OPNt transcripts, 
was significantly increased by 2.5-fold over the control 
cells (Fig. 2c). The expression level of RUNX2 was consid-
erably increased in the RUNX2-overexpressing A549 cells 
(Fig.  2d). In comparison with the vector control group, 
overexpressing RUNX2 resulted in a significant change 
in the expression levels of OPN-SIs (Fig. 2e). The normal-
ized abundance of OPNc was increased by approximately 
2.3-fold, whereas no expression change was found in 
OPNa and OPNb (Fig. 2f). When cells transfected with a 
 RUNX2R131G mutant, which lacks the binding ability to 
OPN promoter for transactivation activity (as shown from 
the reporter assays), responses in the mRNA level changes 
in OPNt and OPN-SIs were abolished (Additional file1: 
Figure S2). Consistently, the TGF-β induced opn expression 
was also found significantly compromised in the RUNX2 
knockdown A549 cells (Fig. 2g). These data suggested that 
TGF-β not only induced the mRNA transcription of Opn 
gene, but also regulated the outcome of alternative splic-
ing of opn mRNA. The transcription factor RUNX2 of its 
increased levels in TGF-β induced EMT cells could be 
involved in the splicing of OPN-SIs, and the RUNX2 reg-
ulation on OPN splicing was possibly require the binding 
of RUNX2 to OPN promoter at the interaction motif sites. 
Among the major forms of OPN-SIs, a less abundant OPNc 
appeared to be a more sensitive indicator for representing 
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the regulating role of TGF-β on OPN splicing in NSCLC 
cells.
The splicing of OPNb and OPNc required the splicing 
regulatory factor SRSF1
The splicing factor SRSF1 is a crucial family member of 
SR proteins. SRSF1 was known to bind exonic splicing 
enhancers to promote splicing [20]. It has been reported 
that SRSF1 was able to regulate EMT through disrupting 
the alternative splicing of key tumor associated genes, 
including Ron proto-oncogene [21], PRRC2C [22], and 
MKNK2 [23, 24], to modulate lung cancer progression. 
To investigate the role of SRSF1 on OPN alternative 
splicing, we tested if changes of SRSF1 expression could 
affect OPN splicing in A549 cells. Knocking down of 
SRSF1 (Fig. 3c) through the transfection with SRSF1 tar-
geted siRNAs in A549 cells markedly reduced the splic-
ing products of OPNb and OPNc from the isolated total 
RNAs (Fig. 3a) and in the splicing reporter assay (Fig. 3b). 
Therefore, SRSF1 is able to boost the splicing of OPNb 
and OPNc both in genomic transcription coupled splic-
ing and the naked RNA from plasmid transcription.
RUNX2 increased OPNc splicing in a HDAC dependent 
manner
Histone deacetylases (HDACs) repress gene transcrip-
tion by deacetylating histone and non-histone proteins 
[25]. HDACs induce chromatin changes and are involved 
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Fig. 1 Upregulation of RUNX2 associated with increased OPN expression during the EMT progression in TGF-β treated A549 cells. a TGF-β 
treatments for 48 h increased cell migration. b TGF-β treatments induced significant changes in the expression of major EMT marker genes at 
both mRNA (left) and protein (right) levels. c The mRNA (upper) and protein (lower) expression of OPN and RUNX2 were synchronically increased 
following TGF-β treatments
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levels. g Knockdown of RUNX2 expression attenuated TGF-β induced opn expression in A549 cells
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in regulation of alternative splicing [26]. RUNX2 were 
found to cooperate with HDACs, where RUNX2 medi-
ated HDAC-dependent transactivation [27]. Whether 
the cooperative interaction of RUNX2 with HDACs con-
tributed to the alternative splicing of OPN, especially in 
cancer cells following TGF-β induction, was not known 
to date. We treated A549 cells with widely used HDAC 
inhibitors TSA or NaB and found that the enhancement 
of RUNX2 on OPNc splicing was reduced (Fig.  4a–d). 
Using siRNAs to knockdown specific HDAC isoforms, 
we determined that HDAC1 and HDAC2 were responsi-
ble for mediating the splicing of OPNc, with the former 
to be more important. As compared to the scramble con-
trol group, the levels of OPNc was reduced to about 50% 
or 56% respectively following cotransfection of RUNX2 
with siHDAC1 or siHDAC2 (Fig.  4e). Knockdown of 
HDAC3 did not show significant effect on the splicing 
of OPNc. These results suggested that with the depend-
ence to HDAC1 or HDAC2, RUNX2 indeed participated 
and increased OPNc alternative splicing in A549 cells. In 
view of the fact that the EMT process is often accompa-
nied with extensive epigenetic changes, we postulate that 
epigenetic regulation can be a fundamental mechanism 
allowing preferential expression of spliced transcript 
related to progression. Other epigenetic factors might 
also be considered in the emergence of OPNc splicing for 
the determination of selectivity.
OPNc overexpression exhibited a potent role 
on the development of invasive cell phenotype 
and promoted EMT in A549 cells
In order to disseminate the effect of different OPN-SIs 
on cellular functions, we performed migration and inva-
sion assays in A549 cells transfected with OPNa, OPNb 
or OPNc expression plasmids (Fig.  5c). In cell invasion 
assays, the results showed that OPNb or OPNc overex-
pression promoted the invasion of A549 cells by 120% 
and 140%. No significantly difference was found in OPNa 
overexpressed cells compared to the controls (Fig.  5a). 
Overexpression of either of the three OPN-SIs could lead 
to the increase in cell migration by 140%, 150% and 170% 
respectively (Fig. 5b). These results demonstrated OPNc 
displayed a more potent effect to induce EMT-like phe-
notypes in A549 cells than OPNa and OPNb, as shown in 
the western blots of E-cadherin and N-cadherin as EMT 
marker proteins. However, the differences in the expres-
sion of Snail and Slug were not appeared significant even 
under OPNc overexpression conditions (Fig. 5c).
Increase of OPNc splicing and cell migration 
is HDAC‑dependent in SK‑MES‑1 cells under TGF‑β 
induction
To verify our findings on the role of TGF-β on OPN 
splicing, we selected SK-MES-1 cells, a different type of 
NSCLC cell of squamous cell origin, and treated with 
TGF-β (5 ng/ml) for 48 h. The cells exhibited increased 
mobility comparing to the untreat controls (p < 0.001) 
(Fig.  6a). Following TGF-β induction, the mRNA levels 
of OPNt and OPNa, OPNb, OPNc were increased, except 
the changes in transcript levels were less significant as 
a
10 OPNa OPNb OPNc
0.001
0.1
1
** **
*
**
b
scramble siSRSF1-1 siSRSF1-2
c
scramble siSRSF1-1 siSRSF1-2
SRSF1
GAPDH
Fig. 3 Knock down of SRSF1 reduced mRNA levels of OPN-SIs. a 
RNAi of SRSF1 decreased OPNc levels in A549 cells. b Inhibition of 
OPNb and OPNc splicing from reporter assays following SRSF1 siRNA 
transfection. c Western blot of SRSF1 in A549 cells transfected with 
targeted siRNAs
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observed in A549 cells (Fig.  6b). Among all the OPN-
SIs, OPNc remained to be the most increased isoform 
(Fig. 6c). We then directly moved on to evaluate the role 
of HDACs on OPN expression and splicing by co-trans-
fecting siHDAC1 or siHDAC2 with RUNX2 in SK-MES-1 
cells. When HDAC1 was knocked down, the levels of 
OPNc was reduced to approximately 77%. Similar results 
of about 75% was observed in HDAC2 RNAi samples 
as compared to the scramble control group (Fig.  6d, 
e). In Fig.  6f comparing the effect of OPNa, OPNb and 
OPNc on cell migration, OPNc was again demonstrated 
for most significant role to promote cell mobility in SK-
MES-1 cells. These results were consistent with our 
observation in A549 cells, and therefore indicated that 
the increase of TGF-β induced cell migration involved 
enhanced OPNc splicing, meanwhile the OPNc splicing 
was regulated by RUNX2 and appeared to be HDAC-
dependent. Such regulatory scheme could be a common 
mechanism in different cancers and to affect cancer cell 
migration.
a
b
RUNX2
vector
TSA
RUNX2
untreat TSAuntreat
d vector
N B
RUNX2
t t N Bt t
c
GAPDH
OPN
RUNX2
OPN
aun rea aun rea
RUNX2
GAPDH
e
f vector RUNX2
scramble scramble siHDAC1 siHDAC2 siHDAC3
HDAC2
HDAC1
OPN
GAPDH
HDAC3
Fig. 4 RUNX2 dependent OPNc splicing required normal activities of HDAC1 or HDAC2. a Treatment of A549 cells with HDACs inhibitor TSA 
suppressed OPNc splicing induced by RUNX2 overexpression. b Western blot of RUNX2 and OPN in RUNX2 overexpressed A549 cells following 
TSA treatment. c Inhibition of HDAC1 activity by NaB deprived RUNX2 induced OPNc splicing. d Western blot of RUNX2 and OPN in RUNX2 
overexpressed A549 cells treated with NaB. e Knockdown of HDAC1 or HDAC2, but not HDAC3, decreased RUNX2-induced OPNc splicing. f Western 
blots of HDAC1, HDAC2 and HDAC3 from A549 cells transfected with the targeted siRNAs
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Clinical association of OPN‑SIs in NSCLC patients
Following the exact protocol to determine OPNa levels 
[16], we quantified the transcript abundance of OPNb 
and OPNc for using samples from the same tissue bank. 
A significantly increased level of OPNc (p = 0.0071) was 
found in the in cancer group (Fig.  7a). Noticeably, the 
elevated level of OPNc appeared to be more frequent 
in samples with low tumor differentiation, positive 
lymph node metastasis and high TNM stage, despite not 
reached for a statistical significance among these groups. 
When the NSCLC tissues were classified into two sub-
groups according to the median OPNc level, the high 
OPNc group was demonstrated a shorter overall survival 
index as compared to the low OPNc patients (Fig.  7b). 
This could be a piece of supporting evidence for OPNc 
to be used as a marker for EMT emergence and progress, 
which indicates more malignant features of NSCLC.
Discussion
The role of alternative splicing (AS) during EMT has 
increasingly been recognized recently. AS regulates a 
broad spectrum of genes involved in cancer progression 
and metastasis. AS variants orchestrate several impor-
tant process defining EMT phenotypes, including cell–
cell contacts, polarity and cytoskeleton organization, and 
differentiation. Under many circumstances, the pivotal 
role of AS regulation in tumor plasticity is underscored 
for its complex consequence, where the rapid shifts of 
the expression of protein isoforms may exhibit distinct 
functions and are affected by many factor. However, loss 
of splicing fidelity indeed resulted in the production of 
the isoforms of various proteins controlling numerous 
facets of cancer. Although changes in AS occur during 
EMT, only a small portion of specific splicing events are 
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1 0
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Fig. 5 OPNc overexpression was most potent to induce an invasive phenotype in A549 cells among OPN-SIs. a Overexpression of OPNb and OPNc 
significantly increased the invasiveness of transfected cells. b Overexpression of OPN-SIs promoted cell mobility and migration. c Immunoblots of 
EMT marker proteins in cells with overexpression of OPN-SIs
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known to functionally contribute to EMT and its regu-
lation, such as the splicing of CD44, FGFR2 and Exo70 
[28–30]. In the present study, a notable EMT associated 
splicing isoform OPNc was identified and verified for its 
increased presence in TGF-β induced A549 cells (Fig. 2). 
In NSCLC cancer tissues, it was also indicated that high 
level expression of OPNc significantly associated with the 
shorter overall survival of patients (Fig. 7), but not OPNa 
or OPNb (Additional file 1: Figure S3). OPNc was dem-
onstrated to play a stronger role to promote the capabil-
ity of cell migration and invasion in A549 cells, which 
was required during the development and advancing 
of EMT (Fig.  5). These data helped to explain the fact 
that the patients with lower tumor differentiation, more 
lymph node metastasis and higher TNM stages tends to 
exert high levels of OPNc transcripts (Fig. 7). Our results 
suggested that OPNc expression could be an important 
marker to indicate the development of EMT and the 
malignant progression of NSCLCs.
The splicing isoforms of OPN have been connected to 
be cancer progression in several tumors, yet the under-
standing of the mechanism for their generation and regu-
lation are still very poor. Splicing is reported to involve 
the interaction between RNA binding proteins (RBPs) 
via presumably the cognate splicing regulatory sequence 
elements (SREs) in the premature mRNAs. A major class 
of splicing factors that control splice site recognition is 
the families of Serine/Arginine-rich (SR) proteins, which 
interact with heterogeneous nuclear ribonucleoproteins 
(hnRNPs). As a well characterized factor, SRSF1 was 
suggested to play key driver functions in solid tumors. 
Considering the possibility that different types of splic-
ing events might recruit specific regulators, such as the 
finding in FLNB mediated EMT of its FOXC1 depend-
ent skipping of exon 30 [31], we investigated the role 
of SRSF1 for the splicing of Opn gene in NSCLC cells 
(Fig. 3).
Alternative splicing by its nature is a tightly controlled 
process, despite the types of splicing events and the out-
come in splicing variants are in great varieties, especially 
during EMT where the selection alternative splice site, 
choices for retaining introns or using alternative exons 
can be rather sophisticate. A subset of genes spliced with 
exclude exons and switched from longer to shorter iso-
forms in EMT cells, such asSLC37A2, KIF13A, FLNB, 
and MBNL1, while others showed a greater degree of 
exon inclusion, e.g. PLEKHA1, MLPH, ARHGEF11, 
CLSTN1 and PLOD2 [32]. Exon inclusion events might 
require remodeler A, vs. exon exclusion events, which 
might require remodeler B. Alternatively, there might be 
certain transcription factors that can specifically target 
different sets of chromatin remodelers to different genes, 
e.g. inhibition of the E-cadherin promoter transcription 
with ZEB1 expression increases E-cadherin aberrant 
splicing. RUNX2 belongs to the RUNX family, plays a 
role in several tumor tissues, including pancreatic cancer, 
a b
Variable N Median(IQrange) p Value
Tissue samples
Normal 90 13 (1,302)
Tumor 92 250 (7, 1670) 0.0071**
Smoking history
Yes 51 593 (24, 2325)
No 27 134 (4, 1066) 0.59
Histology
Adenocarcinoma 41 353 (9, 3346)
S uamous carcinoma 30 203 3, 1505 0.071q ( )
Lymphynode status
N0 36 190 (3, 1285)
N1 15 573 (48, 1727) 0.59
N2 26 483 (26, 4621) 0.68
N2+3 41 573 (40, 3346) 0.89
TNM staging
TNM1 24 233 (5, 1285)
TNM2 18 266 (19, 1066) 0.49
TNM3 35 613 32 4540 0.28( , )
Differentiation
High-Medium 5 4 (1, 1156)
Medium 36 282 (36, 3171) 0.074
Medium-Low 14 353 (4, 1404) 0.36
Low 11 102 (1, 4865) 0.30
Fig. 7 OPNc expression in association with clinical features of NSCLC patients. a Demographic information of collected NSCLC tissues and statistics 
from quantitative PCR analyses of OPNc expression. b Overall survival of patients with NSCLC cancer in OPNc high and OPNc low groups
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breast cancer, ovarian epithelial cancer, prostate cancer, 
and osteosarcoma [33–37]. By analyzing public databases 
for recurrent RUNX2 genetic and epigenetic modifica-
tions in lung cancer, we found that the most common 
RUNX2 genetic alteration that exists in transcription 
upregulation is, followed by genomic amplification, 
nucleotide substitution and multiple changes (Additional 
file  1: Figure S4). RUNX2 was reported to modulate 
expression and secretion of the OPN in osteosarcoma 
cells to promote adhesion to endothelial pulmonary cells 
and lung metastasis. However, the transcription regula-
tion of RUNX2 on OPN in lung cancer is still not clear. 
There is no report about the regulating role of RUNX2 
on splicing yet. In the present study, it was found that 
RUNX2 not only enhanced the mRNA transcription of 
Opn gene, but also regulated the AS of OPN (Fig. 2).
The kinetic coupling model for splicing regulation 
partly explains the role of transcription factors for influ-
encing the rate of transcription elongation which leads to 
the occurrence of alternative splicing in many occasions. 
There is also additional evidence demonstrating transcrip-
tion factors interfere the splicing events through directly 
interacting with the spliceosome, or by recruitmenting 
additional regulatory factors. As the most populated chro-
matin remodelers, HDACs are thought to be and are dem-
onstrated as functional epigenetic modulators to bridge 
the role of transcription factors in both of the transcription 
and splicing process. It was reported that RUNX2-induced 
Opn gene expression was under HDAC1-mediated regu-
lation in C3H10T1/2 cells. Additionally, HDAC1 and the 
non-phosphorylated form of HDAC2 were found to co-
precipitate with SRSF1, as shown by mass spectrometry 
followed by immunoprecipitation [38]. The present studies 
suggested that the dependence of HDAC1 and HDAC2 on 
OPNc splicing induced by RUNX2 overexpression (Fig. 4) 
possibly revealed the importance of HDACs for coordi-
nating the couple events of transcription and splicing in 
eukocytes. A splicing complex maintained dynamically 
by SRSF1 and HDACs would be sensitive to the binding 
of RUNX2 to Opn promoter, as these sharing for the same 
pool of HDACs. The binding of RUNX2 to Opn promoter 
for activation of Opn transcription which was repressed by 
the interaction with HDACs, could redistribute and shunt 
the HDACs from the upstream to the splice sites and 
interact with SRSF1, leading to the increase of Opn splic-
ing. The epigenetic mechanisms should be emphasized in 
the process of mRNA splicing especially in the transcrip-
tion coupled splicing. The role of HDAC family members 
could be dominant in the regulation of alternative splic-
ing. On top of upregulating the gene transcription follow-
ing the transactivation of its promoter, such mechanisms 
are able to further translate a physiological stimulation, 
such as TGF-β induction, into a response to selectively 
amplify specific splicing variant species and producing 
corresponding protein isoforms for developing certain 
phenotypes. For EMT in lung cancer cells, the increased 
expression of OPNc not only directly promoted the inva-
siveness of cells, but also could be a solution to maintain 
the continuation of EMT development by attenuating 
or circumventing the dominance of TF controls on gene 
expression, which tends to be pro-proliferative and often 
fluctuated in cancers.
Conclusion
In conclusion, our study discovered that the selective 
splicing of OPNc could be regulated by RUNX2 or SRSF1 
in a HDAC depending manner. The findings improved 
the understanding about how OPNc appeared to be a 
better-performed marker to indicate the development 
of EMT in NSCLC. The phenotype changes in migra-
tion and invasion for cells undergo EMT involve complex 
interactions of transcription factors and epigenetic pro-
teins, which lead to the spectrum changes in splicing var-
iants, as well as the selective production of specific SIs. 
The epigenetic mechanisms for the regulation of gene 
expression will also be important for the modulation 
of alternative splicing, at least the role of HDAC fam-
ily members should be emphasized in related studies on 
EMT and cancer metastasis.
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Additional file 1: Figure S1. The design of OPN splicing minigenes. The 
splicing minigene cassette of pGL3-OPNSIb-luc contains the fusion of 
exon 4, initial 300 bp of intron 4, last 300 bp of intron 4, exon 5, intron 
5 and exon 6 of the Opn gene at upstream of firefly luciferase CDS. 
Similarly, the pGL3-OPNSIc-luc minigene contains fused segments of the 
Opn gene in the order of exon 3, initial 300 bp of intron 3, last 300 bp of 
intron 3, exon 4, intron 4 and exon 5. The stop codons were engineered 
at the end of the alternative spliced exons, i.e. exon 4 or 5 in each of the 
two constructs. Figure S2. The mRNA levels of OPN and OPN-SIs were 
not influence by overexpression of RUNX2 mutant without the binding 
activity for the transactivation of OPN promoter. a Western blots of wild 
type RUNX2 or  RUNX2R131G mutant in transfected A549 cells. b Reporter 
assays using 6 × RUNX2 driven luciferase expression for the detection 
on the transcriptional activity of RUNX2 and  RUNX2R131G mutant. c The 
mRNA expression of OPNt, OPNa, OPNb and OPNc were not significantly 
changed following transfection of  RUNX2R131G mutant. d No significant 
difference was observed comparing the normalized mRNA abundance 
of OPNa, OPNb and OPNc in A549 cells tranfected with the  RUNX2R131G 
overexpression plasmids. Figure S3. The overall survival of patients with 
NSCLC tissues analyzed by OPNa and OPNb expression levels. a The 
overall survival of NSCLC patients by OPNa levels. b The overall survival in 
association with OPNb levels. Figure S4. Genetic alterations detected of 
human RUNX2 gene in lung cancers as documented in the public data-
bases. a The data on gene mutation, amplification and multiple alterations 
of RUNX2 retrieved from cBioPortal as filtered in lung adenocarcinoma 
and lung squamous cell carcinoma. b The statistics of RUNX2 expression 
in lung adenocarcinoma using data collected in TCGA database.
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